Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Chief Financial Officer | March 07, 2025 | March 11, 2025 |
| Sonnet BioTherapeutics Holdings, Inc.SONN · Entity 72220 | Chief Financial Officer | December 11, 2023 | December 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senti Biosciences Holdings, Inc.
Report date March 07, 2025 · Filed March 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.52 · Expires 2035-03-06 | Direct | 174,200 |
Reported balance
After 2025-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-07 · Grant · Acquired 174,200 · Balance 174,200 F1: 25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.
Sonnet BioTherapeutics Holdings, Inc.
Report date December 11, 2023 · Filed December 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,588 |
Reported balance
After 2023-12-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-11 · Grant · Disposed 1,452 · Balance 1,588 F1: On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025. F2: Includes unvested restricted stock units. F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025.
F2: Includes unvested restricted stock units.
F3: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2025 Filed Mar 11, 2025 20:14 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 174,200 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001854270-25-000026 · wk-form4_1741724083.xml · derivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,200 Underlying: Common Stock · 174,200 shares Expires 2035-03-06 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 11, 2023 Filed Dec 6, 2024 02:55 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 1,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-048950 · ownership.xml · nonDerivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,588 F1 · price: On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025. F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. Read SEC document |
| February 06, 2023 Filed Feb 17, 2023 21:45 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | Tax withholdingCommon Stock | 1,960 | $1.06 | $2,077.60 |
DisclosureSEC source: 0001493152-23-005464 · ownership.xml · nonDerivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,927 F1 · balance_after: Includes unvested restricted stock units. Read SEC document |
| December 14, 2022 Filed Dec 22, 2022 21:31 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 15,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-036315 · ownership.xml · nonDerivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,684 F1 · shares: On December 14, 2022, the Reporting Person was granted 15,519 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F1 · price: On December 14, 2022, the Reporting Person was granted 15,519 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2024. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| December 15, 2021 Filed Apr 8, 2022 20:30 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 66,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-009485 · ownership.xml · nonDerivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,165 F1 · shares: On December 15, 2021, the Reporting Person was granted 66,951 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. F1 · price: On December 15, 2021, the Reporting Person was granted 66,951 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2023. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 22:17 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 78,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012570 · ownership.xml · nonDerivative · entry 1 Cross John Harry III · CIK 0001806763 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,214 F1 · shares: On July 2, 2020, the Reporting Person was granted 78,214 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 50% of the restricted stock units on April 2, 2021 and 50% of the restricted stock units on April 2, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.